戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              HAMA levels were many times greater in amount than HATA
2                                              HAMA response occurred in five of six patients.
3                                              HAMA was determined in two patients.
4 l cancer patients, and only rarely induces a HAMA response.
5 tion, but does induce a human anti-mouse Ab (HAMA) response despite strong concurrent immunosuppressi
6 surement of human antimonoclonal antibodies (HAMA).
7                  Human antimouse antibodies (HAMA) did not develop in the patients after treatment.
8 tients developed human antimouse antibodies (HAMA) to CEA-Scan after a single injection, and none of
9 ients developed human antimurine antibodies (HAMA) after RIT.
10                 Human antimurine antibodies (HAMA), anti-I-Mel-2 antibodies, and specific antibody (A
11                 Human anti-mouse antibodies (HAMA) developed in all but one of the six patients who r
12 ts negative for human anti-mouse antibodies (HAMA).
13                    Human antimouse antibody (HAMA) response, adverse events, clinical laboratory valu
14 baseline anti-SEA, human antimouse antibody (HAMA), CA242-soluble antigen levels, and T-cell receptor
15 patients due to a human anti-mouse antibody (HAMA) response.
16 etics, dosimetry, human anti-mouse antibody (HAMA), toxicity and clinical responses were evaluated.
17  95% CI, -0.29 to 2.68; P = .11) or anxiety (HAMA mean difference, 1.16; 95% CI, -0.18 to 2.51; P = .
18 peated injection, in no patient did elevated HAMA titers develop, hematology and serum chemistry chan
19 e CI regimen made antibody against mouse Ig (HAMA) and/or ricin A chain antibody (HARA).
20 g human anti-mouse antibody (immunoglobulin; HAMA) responses in patients, however, limits the use of
21                                           No HAMA were detectable in either patient, and no adverse r
22 bited acceptable toxicities, and elicited no HAMA formation.
23 ating Scale (MADRS), Hamilton Anxiety Scale (HAMA), Clinical Global Impression scale (CGI), and Veter
24 ed, to allow the use of RIT and can suppress HAMA responses.
25                           Rapid onset of the HAMA response will hinder multicycle therapy, unless it

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。